- Home
- KLG vs AGIO Comparison
KLG vs AGIO Comparison
Compare KLG & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLG
- AGIO
- Stock Information
- Founded
- KLG 2022
- AGIO 2007
- Country
- KLG United States
- AGIO United States
- Employees
- KLG N/A
- AGIO N/A
- Industry
- KLG Packaged Foods
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- KLG Consumer Staples
- AGIO Health Care
- Exchange
- KLG Nasdaq
- AGIO Nasdaq
- Market Cap
- KLG 1.6B
- AGIO 1.4B
- IPO Year
- KLG N/A
- AGIO 2013
- Fundamental
- Price
- KLG $16.91
- AGIO $32.09
- Analyst Decision
- KLG Sell
- AGIO Buy
- Analyst Count
- KLG 7
- AGIO 8
- Target Price
- KLG $16.86
- AGIO $56.00
- AVG Volume (30 Days)
- KLG 853.9K
- AGIO 550.4K
- Earning Date
- KLG 05-06-2025
- AGIO 05-01-2025
- Dividend Yield
- KLG 3.90%
- AGIO N/A
- EPS Growth
- KLG N/A
- AGIO N/A
- EPS
- KLG 0.65
- AGIO 11.45
- Revenue
- KLG $2,664,000,000.00
- AGIO $37,035,000.00
- Revenue This Year
- KLG N/A
- AGIO $27.43
- Revenue Next Year
- KLG N/A
- AGIO $189.81
- P/E Ratio
- KLG $25.95
- AGIO $2.80
- Revenue Growth
- KLG N/A
- AGIO 25.96
- 52 Week Low
- KLG $14.80
- AGIO $23.42
- 52 Week High
- KLG $22.21
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- KLG 39.33
- AGIO 65.51
- Support Level
- KLG $16.79
- AGIO $29.05
- Resistance Level
- KLG $17.68
- AGIO $30.45
- Average True Range (ATR)
- KLG 0.47
- AGIO 1.13
- MACD
- KLG -0.02
- AGIO 0.33
- Stochastic Oscillator
- KLG 7.69
- AGIO 91.98
About KLG WK Kellogg Co
WK Kellogg is the second-largest cereal manufacturer in North America. Its cereal brands include Special K, Frosted Flakes, Raisin Bran, Froot Loops, Frosted Mini-Wheats, Kashi, Corn Flakes, Rice Krispies, Apple Jacks, and Bear Naked. The company was spun off from the former Kellogg business, now known as Kellanova, where the former firm's global snacks portfolio and international cereal brands are now housed. WK Kellogg, which began trading independently in October 2023, generates the bulk of its sales (about 88% of its fiscal 2024 base) in the US.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.